Fierce Pharma September 16, 2024
Sponsored by Osmind

By Dr. L. Alison McInnes and Jimmy Qian

We’re finally moving towards a causality-based nosology for psychiatry: specific symptoms with defined biological underpinnings can now be targeted by new therapies. But how do we bridge clinical development with real-world care? How do we ensure trial endpoints are synchronized with real-world measures, payer requirements, and clinical society guidelines? Below, we dig into the widening gap between research and clinical care.

No consensus on how to measure transdiagnostic symptoms

Excitingly, researchers have been able to characterize underlying neural circuitry for certain symptoms. The NIMH Fast-Fail Trials initiative, which stipulated that a drug candidate should alter a biomarker in an objectively measurable fashion, accelerated this movement. For anhedonia, investigators identified ventral striatum...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Mental Health, Provider
SonderMind expands nationwide
Gender Gaps in Teen Mental Health Differ by Region
New Hampshire system opens adolescent medical psychiatry unit
82% of physicians fear consequences for seeking mental health treatment
Mental health provider launches AI initiative to train therapists

Share This Article